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Introduction
A rising life expectancy of up to 80 for males and 84 for females 
[1] in our local population has favored an increased use of 
biological prostheses in the surgical treatment of aortic valve 
disease. We started implanting the Mitroflow Model 12A valve 
in 2001 and used it preferentially in the smaller-sized annulus 
due to its excellent haemodynamic performance [2] and ease of 
insertion. In 2006 we switched to the Mitroflow LX in line with the 
manufacturer’s recommendations.
Structural valve degeneration (SVD) has been reported with both 
the 12A and LX models and is thought to relate to the lack of anti-
calcification treatment, [3,4,5] a feature present in other early valve 
models.[6] This complication has been reported with increasing 
frequency in patients under 70 and in the size 19 valve, in severe 
prosthesis-patient mismatch [7,8,9] but also occasionally in 
larger sizes.[10,11] In spite of these clinical situations, long-term 
outcomes in large series have been favorable.[8,9,12,13]
Premature SVD may be under-reported because it is usually 
recognized when re-intervention is indicated.[14] Retrospective 
series of patients receiving the Mitroflow valve and case reports 
with this and other valves [15] have highlighted this clinical problem. 
Comparative studies are, however, sparse. Many elderly patients 
are not candidates for repeat surgery or valve-in-valve transcatheter 
implantation because of co-morbidities or technical considerations 
and so the real impact of SVD may be reflected in premature death. 
We have therefore sought to compare the long-term survival of our 
Mitroflow patients with matched controls receiving other valves in 
order to better understand the clinical relevance of SVD.
ISSN: 2410-2636 © Barcaray Publishing
© 2019 Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution CC-BY-4.0 license CC-BY-4.0 (http://creativecommons.org/
licenses/by/4.0/), which permits use, distribution and reproduction, provided the original work is properly cited. Published by Barcaray (International) Publishing.
Abstract
Background
Recent case reports of early structural degeneration of the Mitroflow valve have cast doubts on the suitability of this bioprosthesis, 
particularly in the smaller sizes, and in younger patients. We studied long-term patient survival, in a comparative study, as a
marker of success after aortic valve replacement.
Methods
Long-term survival in 142 consecutive patients implanted with the Mitroflow valve was compared, using the Kaplan-Meier method, 
with a control group of 149 patients receiving different bioprostheses. Ninety two percent of patients were over 70 years and the 
Mitroflow was used preferentially in smaller sizes.
Results
Long-term survival in patients who received a Mitroflow valve was equivalent to controls. Four documented cases of premature 
structural valve degeneration (3 Mitroflow, 1 Perimount) required a second intervention.
Conclusions 
The Mitroflow compared favorably with other valves in our practice. Although a few patients required further treatment this had no 
significant adverse impact on overall survival.
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Methods
Patients and clinical protocol
All patients undergoing surgical aortic valve replacement in a 
single-surgeon practice between April 1st 1995 and December 
31st 2017 were included in this study. The threshold for 
bioprosthetic valve implantation was set at 70 years and 92% of 
the patients achieved this target.
During the first 6 years (1995-2001) the Carpentier Edwards 
valve was the sole bioprosthesis used. From 2001 onwards the 
Mitroflow valve was introduced and preferentially selected in 
the small annuli. The choice of valves evolved with time in line 
with newer models and international trends. Valves implanted 
included LivaNova Mitroflow (models 12A and LX) 142, 
Carpentier Edwards porcine 62, Carpentier Edwards Perimount 
39, LivaNova Perceval 23, Toronto SPV 10, Carpentier Edwards 
Perimount Magna 9, Carpentier Edwards Perimount Magna Ease 
4 and Intuity Elite 2.
All patients underwent surgery under normothermic 
cardiopulmonary bypass and myocardial protection was with 
antegrade cold blood cardioplegia. Concomitant coronary 
bypass surgery was performed in the standard fashion and 
the graft of first choice was the internal thoracic artery. The 
valves were washed rinsed prior to implantation according to 
the manufacturer’s instructions and patients were discharged 
on aspirin alone unless contra-indicated. Operative technique 
was consistent, apart from the recent introduction of mini-
sternotomy approach for isolated aortic valve replacement. 
Severe prosthesis-patient mismatch was defined as an indexed 
effective orifice area (iEOA) of 0.65cm2/m2 or less (Pibarot16). The 
Mitroflow cohort was compared to the cohort of all the other 
biological valves.
Follow-up
All patients were followed up at our institution and underwent 
regular echocardiograms, which were performed with increasing 
frequency when the clinical indication arose. Structural valve 
degeneration was deemed to be present when significant aortic 
stenosis (>40mmHg mean gradient) or regurgitation occurred by 
echocardiographic assessment. The date of death was obtained 
from the National Statistics Office. The primary endpoint of the 
study was post-operative survival duration .
Statistical analysis
Means and standard deviations were used to measure central 
tendency and dispersion for continuous variables and frequency 
tables and crosstabs were used to describe categorical variables. 
Several statistical techniques were used to carry out statistical 
inference. The Chi square test was used to compare proportions 
between two groups, while the Students t-test was used to 
compare means of continuous variables. The Log Rank test was 
used to compare Kaplan-Meier survival curves. A p value less 
than the 0.05 level of significance was taken to indicate statistical 
significance.
Results
Table 1. Summarises summarizes the baseline, operative and 
post-operative data.
Table 1. Data for Mitroflow versus other valve, expressed 
as percentages or mean±SD
parameter Mitroflow other  valves
Chi 
square t-test
sample size (n) 142 149
age 75.18±4.29 74.07±4.29 0.029
age<70 years 5 (3.5%) 18 (12.1%) 0.004
female 83 (58.5%) 56 (37.6%) <0.001
Parsonnet 21.16±6.03 19.13±6.45 0.004
EuroSCORE 6.85±1.42 6.57±1.38 0.122
logistic 
EuroSCORE 7.28±3.08 7.47±4.80 0.772
height 1.54±0.10 1.61±0.09 <0.001
weight 70.59±12.5 76.22±15.49 0.002
body surface area 1.69±0.19 1.80±0.18 <0.001
body mass index 29.36±4.83 29.96±4.77 0.349
ejection fraction 69.17±12.96 68.24±13.38 0.714
diabetes 46/130 (35.4%) 24/77 (31.2%) 0.535
hypertension 89/130 (68.5%) 58/77 (75.3%) 0.294
urgent 23 (16.2%) 17 (11.3%) 0.227
solitary AVR 85 (59.9%) 106(70.7%) 0.052
AVR+ 
graftsCABG
57 (40.1%) 44 (29.3%) 0.052
size 19 28 (19.7%) 4 (2.7%) <0.001
size 21 70 (49.3%) 35 (23.5%) <0.001
size 23 40 (28.2%) 56 (37.6%) 0.096
size 25 4 (2.8%) 54 (36.2%) <0.001
severe mismatch 
<0.65cm2/m2
8 (5.6%) 1 (0.7%) 0.014
valve stenosis 80.0% 74.7% 0.401
valve regurgitation 6.6% 9.2% 0.384
mixed valve 
disease 13.4% 16.1% 0.503
pseudo-bicuspid 28.0% 36.0% 0.234
tricuspid 
degenerative 62.1% 54.7% 0.294
Isolated AVR cross- 
clamp time (min) 54.6±11.2 51.8±11.7 0.127
AVR+CABG cross 
-clamp time (min) 68.7±11.5 71.2±12.1 0.397
intensive care 
stay (days) 1.25±1.68 1.96±9.45 0.376
step-down ward 
stay (days) 4.21±3.18 4.73±3.45 0.180
ventilation (hours) 13.27±32.27 17.45±52.04 0.435
bleeding (ml) 496.5±304.6 499.8±359.9 0.937
death 3 (2.1%) 5 (3.4%) 0.522
dialysis 13 (9.2%) 7 (4.7%) 0.129
cerebrovascular 
accident 0 (0.0%) 1 (0.7%) 0.332
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Demographics
Ninety-two percent of the patients over 70 years received a 
bioprosthesis. Younger patients accounted for a significantly 
higher percentage (12.1% versus 3.5%, p=0.004) with other 
valves (16 patients: 65-70, 2 patients:60-65) than with Mitroflow 
valves (5 patients: 65-70). There was a trend towards avoiding a 
bioprosthesis in younger patients with time: 13 patients during 
the first 7 years versus 10 patients during the last 16 years. 
Mean age (p=0.029) and female preponderance (p<0.001) 
were significantly higher in the Mitroflow group. Parsonnet risk 
was higher in the Mitroflow group (p =0.004) , but additive and 
logistic EuroSCORE were similar. Body surface area was smaller 
(p<0.001) in the Mitroflow group. The incidence of hypertension 
and diabetes was similar.
Operative data
Operative urgency, valve pathology and concomitant coronary 
surgery were similar. There were significantly more size 19 
(p<0.001) and size 21 (p<0.001) and significantly fewer size 25 
(p<0.001) valves implanted in the Mitroflow group. Size 23 valves 
were equally implanted in the two groups. There were 8 cases 
of severe prosthesis patient mismatch in the Mitroflow group, 
all with size 19 (iEOA 0.54-0.65cm2/m2) and one case with a 
Perceval S valve (iEOA 0.61cm2/m2 ) (p=0.014). Cross-clamp time 
was similar for the two cohorts .
Structural valve degeneration (SVD)
A 91 year-old female patient developed clinically relevant stenosis 
and regurgitation 11 years following implantation of a 23mm 
Mitroflow 12A valve (age at implant 80 years). She was treated 
successfully with a Corevalve TAVI valve-in-valve procedure and 
is presently well, aged 95.A 79 year-old male patient developed 
significant regurgitation 9 years after implantation of a 23mm 
Mitroflow LX valve (age at implant 70 years) and underwent a 
Corevalve TAVI valve-in-valve procedure. Although he initially 
improved this patient died within a year.
A 77 year-old female patient developed significant stenosis and 
regurgitation 7 years after implantation of a 21mm Mitroflow LX 
(age at implant 70 years) for rheumatic valve disease. She was 
hospitalized with a lobar pneumonia exacerbating congestive 
heart failure. In view of worsening concomitant mitral stenosis 
she underwent redo aortic and mitral valve replacement, but 
died post-operatively of sepsis. The explanted valve exhibited 
thickened leaflets with reduced mobility, and a single tear adjacent 
to a strut. Radiography revealed mild diffuse calcification with 
more prominent calcification localized to two adjacent leaflets 
close to the affected strut (figure 1). A 79 year-old female patient 
presented with symptomatic severe aortic stenosis 7 years 
after implantation of a 21mm Perimount valve (age at implant 
72 years). She underwent a successful Corevalve TAVI valve-in-
valve procedure.
Long-term survival
Maximum follow-up was 22 years (whole population 6.63±4.81, 
Mitroflow 6.10±3.89, other valves 7.13±5.50). Follow-up for 
the Mitroflow group was shorter than for other valves as it was 
introduced later into our practice. Long-term survival after Mitroflow 
implantation was equivalent to controls, with similar Kaplan-Meier 
curves (figure 2). Log-Rank (Mantel-Cox) test yields a non-significant 
difference between the two survival curves (p=0.336).
Post-operative data
There were 8 post-operative deaths (2.75%), 3 in the Mitroflow 
group and 5 in the control group (p=0.522). Ventilation time, 
hospital stay, and complications were similar in the two groups.
Discussion
A rising life expectancy accounted for a progressively conservative 
trend in bioprosthetic valve use. The lower incidence of Mitroflow 
use below the age of 70 years compared with other valves 
reflects the fact that is was introduced later. The mean age in our 
study exceeds that in other large series [16] as we aimed to use 
a bioprosthetic valve in patients over 70 years unless there was 
a contraindication to anticoagulation or life expectancy deemed 
to be limited. There is evidence that the use of mechanical valves 
in patients aged 50-69 results in significantly better long-term 
survival as well as a reduced rate of intervention.[17] Age and 
comorbidities at the time of surgery significantly affect long-
term survival.[16,18,19] Although up to 30% of patients are 
known to exhibit subclinical valve degeneration on echo, with 
an increase of >10mm Hg in mean trans-valvular gradient, 
clinically relevant SVD is infrequent. Less than half of the latter 
patients undergo a further procedure because of limiting co-
morbid conditions.[16] Age therefore exerts a larger impact on 
long-term survival than SVD. In spite of a higher mean age in the 
Mitroflow patients, long-term survival was similar. The Mitroflow 
design with excellent haemodynamics even in smaller sizes may 
have contributed to this outcome, overshadowing the clinically 
relevant SVD that was present in a few patients. Interestingly the 
four patients who developed SVD were all over 70 at the time 
Figure 1  
a)  Explanted Mitroflow valve showing thickened leaflets and a 
tear adjacent to a strut. 
b)  Radiography reveals speckled calcification adjacent to this 
strut.
Figure 2  
Kaplan-Meier survival curves for patients receiving Mitroflow or 
other valve
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of their first surgical intervention and none of the patients with 
severe prosthesis-patient mismatch developed clinically relevant 
SVD. The higher proportion of patients under 70 in the control 
group may have adversely affected the outcome by way of 
accelerated degeneration known to occur in younger patients.
[20] The risk of redo surgery after an aortic bioprosthetic implant 
is higher in men and increases in patients under 70 years of age.
[21] Conversely age at surgery exerts a significant hazard ratio 
for reduced long-term survival, by a factor of approximately 7% 
per annum.[19] The interplay of both these factors is thought to 
have contributed to the outcome of this study. We believe the 
excellent long-term results with the Mitroflow valve in this series 
were achieved when it was implanted in patients over 70 years 
(n=137) keeping younger patients (n=5) to a minimum.
The Crown PRT, incorporating phospholipid reduction treatment 
in its manufacturing process has been developed by LivaNova to 
address early SVD, but retaining the excellent hydrodynamics of 
its predecessor [22]. Time will tell if this new model can achieve 
better long-term results than the Mitroflow.
Limitations
The study is relatively small and confined to a single surgeon 
practice. Sub-clinical SVD was not investigated and impending 
clinically relevant SVD may be underestimated. Minor variations 
in the two groups may have exerted an effect on the outcome.
Conclusion
Long-term survival after aortic valve replacement with the 
Mitroflow valve was similar to that in controls. A few Mitroflow 
patients developed clinically relevant SVD requiring a second 
intervention. However these sporadic episodes did not affect 
the excellent overall results in this population. We believe that 
implanting the Mitroflow valve in patients over 70 whenever 
possible contributed to this.
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